{"id":"ct-388","_chembl":{"chemblId":"CHEMBL4297274","moleculeType":"Small molecule","molecularWeight":"533.80"},"_dailymed":null,"_scrapedAt":"2026-03-28T03:29:42.290Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123810,"model":"claude-sonnet-4-5-20250929"},"description":"CT-388 is an investigational drug being developed by Carmot Therapeutics, Inc., currently in Phase 2 clinical trials. Limited public information is available regarding its molecular target, mechanism of action, or specific therapeutic indications at this time.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT07351058","phase":"PHASE3","title":"A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-03-31","conditions":"Obesity or Overweight, Type 2 Diabetes Mellitus","enrollment":1600},{"nctId":"NCT07351045","phase":"PHASE3","title":"A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight Without Type 2 Diabetes","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-03-31","conditions":"Obesity or Overweight","enrollment":2000},{"nctId":"NCT06525935","phase":"PHASE2","title":"A Study of CT-388 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity","status":"COMPLETED","sponsor":"Carmot Therapeutics, Inc.","startDate":"2024-08-16","conditions":"Obesity, Overweight","enrollment":469},{"nctId":"NCT06628362","phase":"PHASE2","title":"A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Carmot Therapeutics, Inc.","startDate":"2024-11-21","conditions":"Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)","enrollment":360},{"nctId":"NCT04838405","phase":"PHASE1","title":"A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Carmot Therapeutics, Inc.","startDate":"2021-04-29","conditions":"Diabetes","enrollment":129}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RO7795068","RG6640"],"phase":"phase_2","status":"active","brandName":"CT-388","genericName":"CT-388","companyName":"Carmot Therapeutics, Inc.","companyId":"carmot-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CT-388 is a small molecule, specifically a dual GLP-1 and GIP receptor agonist/modulator. It is designed to be administered as a once-weekly subcutaneous injection and has been shown to result in an average 18.8 percent placebo-adjusted weight loss in a 24-week trial.","enrichmentLevel":2,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}